CRISPR/Cas9: Molecular Tool for Gene Therapy to Target Genome and Epigenome in the Treatment of Lung Cancer

Overview

Journal Cancer Gene Ther

Specialties Genetics
Oncology
Pharmacology

Date 2015 Oct 24

PMID 26494554

Citations 26

Authors

M Sachdeva

N Sachdeva

M Pal

N Gupta

I A Khan

M Majumdar

A Tiwari

Affiliations

Soon will be listed here.

Abstract

Although varied drugs and therapies have been developed for lung cancer treatment, in the past 5 years overall survival rates have not improved much. It has also been reported that lung cancer is diagnosed in most of the patients when it is already in the advanced stages with heterogeneous tumors where single therapy is mostly ineffective. A combination of therapies are being administered and specific genes in specific tissues are targeted while protecting normal cell, but most of the therapies face drawbacks for the development of resistance against them and tumor progression. Therefore, therapeutic implications for various therapies need to be complemented by divergent strategies. This review frames utilization of CRISPR/Cas9 for molecular targeted gene therapy leading to long-term repression and activation or inhibition of molecular targets linked to lung cancer, avoiding the cycles of therapy.

Citing Articles

Advances in delivery systems for CRISPR/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles.

Song Z, Tao Y, Liu Y, Li J Front Immunol. 2024; 15:1444437.

PMID: 39281673 PMC: 11392784. DOI: 10.3389/fimmu.2024.1444437.

Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies.

Singh D AAPS PharmSciTech. 2024; 25(5):129.

PMID: 38844700 DOI: 10.1208/s12249-024-02834-6.

High-efficiency targeted transgene integration via primed micro-homologues.

Wang C, Fang S, Chen Y, Tang N, Jiao G, Hu Y Cell Discov. 2023; 9(1):69.

PMID: 37402729 PMC: 10319781. DOI: 10.1038/s41421-023-00552-0.

Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction.

Rabaan A, AlSaihati H, Bukhamsin R, Bakhrebah M, Nassar M, Alsaleh A Curr Oncol. 2023; 30(2):1954-1976.

PMID: 36826113 PMC: 9955208. DOI: 10.3390/curroncol30020152.

CRISPR-mediated MECOM depletion retards tumor growth by reducing cancer stem cell properties in lung squamous cell carcinoma.

Ma Y, Kang B, Li S, Xie G, Bi J, Li F Mol Ther. 2022; 30(11):3341-3357.

PMID: 35733338 PMC: 9637721. DOI: 10.1016/j.ymthe.2022.06.011.

References

Shan Q, Wang Y, Li J, Zhang Y, Chen K, Liang Z . Targeted genome modification of crop plants using a CRISPR-Cas system. Nat Biotechnol. 2013; 31(8):686-8. DOI: 10.1038/nbt.2650. View

Jiang W, Bikard D, Cox D, Zhang F, Marraffini L . RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol. 2013; 31(3):233-9. PMC: 3748948. DOI: 10.1038/nbt.2508. View

Perez-Pinera P, Kocak D, Vockley C, Adler A, Kabadi A, Polstein L . RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods. 2013; 10(10):973-6. PMC: 3911785. DOI: 10.1038/nmeth.2600. View

Ran F, Hsu P, Lin C, Gootenberg J, Konermann S, Trevino A . Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013; 154(6):1380-9. PMC: 3856256. DOI: 10.1016/j.cell.2013.08.021. View

Ding Q, Regan S, Xia Y, Oostrom L, Cowan C, Musunuru K . Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell. 2013; 12(4):393-4. PMC: 3925309. DOI: 10.1016/j.stem.2013.03.006. View

Mali P, Aach J, Stranges P, Esvelt K, Moosburner M, Kosuri S . CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013; 31(9):833-8. PMC: 3818127. DOI: 10.1038/nbt.2675. View

Jackson A, Burchard J, Schelter J, Chau B, Cleary M, Lim L . Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA. 2006; 12(7):1179-87. PMC: 1484447. DOI: 10.1261/rna.25706. View

Morris S, Kirstein M, Valentine M, Dittmer K, Shapiro D, Saltman D . Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994; 263(5151):1281-4. DOI: 10.1126/science.8122112. View

Cho S, Kim S, Kim J, Kim J . Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol. 2013; 31(3):230-2. DOI: 10.1038/nbt.2507. View

10.

Sorek R, Kunin V, Hugenholtz P . CRISPR--a widespread system that provides acquired resistance against phages in bacteria and archaea. Nat Rev Microbiol. 2007; 6(3):181-6. DOI: 10.1038/nrmicro1793. View

11.

Neggers J, Vercruysse T, Jacquemyn M, Vanstreels E, Baloglu E, Shacham S . Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing. Chem Biol. 2015; 22(1):107-16. DOI: 10.1016/j.chembiol.2014.11.015. View

12.

Hou Z, Zhang Y, Propson N, Howden S, Chu L, Sontheimer E . Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci U S A. 2013; 110(39):15644-9. PMC: 3785731. DOI: 10.1073/pnas.1313587110. View

13.

Li J, Shou J, Guo Y, Tang Y, Wu Y, Jia Z . Efficient inversions and duplications of mammalian regulatory DNA elements and gene clusters by CRISPR/Cas9. J Mol Cell Biol. 2015; 7(4):284-98. PMC: 4524425. DOI: 10.1093/jmcb/mjv016. View

14.

Cradick T, Fine E, Antico C, Bao G . CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 2013; 41(20):9584-92. PMC: 3814385. DOI: 10.1093/nar/gkt714. View

15.

Shi J, Wang E, Milazzo J, Wang Z, Kinney J, Vakoc C . Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol. 2015; 33(6):661-7. PMC: 4529991. DOI: 10.1038/nbt.3235. View

16.

Cheng A, Wang H, Yang H, Shi L, Katz Y, Theunissen T . Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res. 2013; 23(10):1163-71. PMC: 3790238. DOI: 10.1038/cr.2013.122. View

17.

Zhao Y, Dai Z, Liang Y, Yin M, Ma K, He M . Sequence-specific inhibition of microRNA via CRISPR/CRISPRi system. Sci Rep. 2014; 4:3943. PMC: 3909901. DOI: 10.1038/srep03943. View

18.

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude G . Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4(12):915-25. DOI: 10.1038/nrm1261. View

19.

Choi Y, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T . EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010; 363(18):1734-9. DOI: 10.1056/NEJMoa1007478. View

20.

Xu X, Wu L, DU F, Davis A, Peyton M, Tomizawa Y . Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers. Cancer Res. 2001; 61(21):7943-9. View